Publicaciones (21) Publicaciones en las que ha participado algún/a investigador/a

2024

  1. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

  2. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

    Blood, Vol. 144, Núm. 6, pp. 646-656

2023

  1. Efficacy and Safety of Fostamatinib for Immune Thrombocytopenia in Clinical Practice in Spain: Interim Results of Fostames, Our National Fostamatinib Registry

    65th Annual Meeting of the American-Society-of-Hematology (ASH)

  2. Galician Experience with Avatrombopag: Galician Thrombosis and Hemostasis Group

    Blood, Vol. 142, Núm. Supplement 1, pp. 5446-5446

  3. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

    Haematologica

  4. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2022

  1. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products

    Thrombosis Research, Vol. 216, pp. 35-42

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa

    Expert Opinion on Biological Therapy, Vol. 21, Núm. 9, pp. 1165-1171

  4. Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

    Transplantation and Cellular Therapy, Vol. 27, Núm. 4, pp. 311.e1-311.e10

  5. Management of acquired hemophilia A: results from the Spanish registry

    Blood Advances, Vol. 5, Núm. 19, pp. 3821-3829

2020

  1. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain

    BMJ Case Reports, Vol. 13, Núm. 10

  2. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score

    Haemophilia, Vol. 25, Núm. 1, pp. 144-153

  3. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review

    Research and Practice in Thrombosis and Haemostasis, Vol. 3, Núm. 3, pp. 528-541

2017

  1. Effect of myofascial induction therapy on post-c-section scars, more than one and a half years old. Pilot study

    Journal of Bodywork and Movement Therapies, Vol. 21, Núm. 1, pp. 197-204

  2. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2015

  1. Neumonía organizada como forma de presentación de una artritis reumatoide

    Galicia Clínica, Vol. 76, Núm. 3, pp. 127-129